Blocking a specific receptor to treat fatty liver disease
Inhibition of EGF Receptor Prevents and Reverses Non-Alcoholic Fatty Liver Disease
This study is looking at how blocking a specific receptor in the body might help people with non-alcoholic fatty liver disease (NAFLD) by reducing fat in the liver and improving overall liver health, which could lead to new treatment options beyond just diet changes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10762482 on NIH RePORTER |
What this research studies
This research investigates the effects of inhibiting the EGF receptor to prevent and reverse non-alcoholic fatty liver disease (NAFLD) and its progression to more severe liver conditions. The approach involves using animal models to observe how blocking this receptor can eliminate fat buildup in liver cells and improve liver health. By understanding the mechanisms involved, the research aims to identify potential new treatments that could be more effective than current dietary modifications. Patients may benefit from a pharmacological treatment option that addresses the underlying causes of their liver disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
Not a fit: Patients with alcoholic liver disease or those who do not have fatty liver disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment for fatty liver disease that significantly improves liver health and reduces the risk of severe complications.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting liver health, indicating potential for success in this area.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Michalopoulos, George K — University of Pittsburgh at Pittsburgh
- Study coordinator: Michalopoulos, George K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.